About
Kasper Roet, PhD, is the CEO and co-founder of QurAlis, a biotechnology company developing precision medicines for ALS and other neurodegenerative diseases. QurAlis also states that he is co-founder and a board director of EnClear Therapies. His background is in neuroscience, gene therapies, and stem-cell-based precision medicine, with training at the Netherlands Institute for Neuroscience, the Free University of Amsterdam, Johnson & Johnson, and Harvard-linked ALS research circles.
Areas of interest
biotechneuroscienceALSneurodegenerative diseaseprecision medicinegene therapystem cell technologyRNA therapeutics